“Right-to-Try” experimental drugs: an overview

Abstract

Abstract The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of “cutting edge” scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, data driven clinical decisions and risk mitigation are reviewed.

Keywords

• “Right-to-Try” experimental drugs
• Precision medicine
• EHR
• Artificial intelligence
• Machine learning
• Panomics